Case report of curative resection after preoperative bevacizumab and sintilimab therapy in hepatocellular carcinoma with lymph node metastasis

肝细胞癌淋巴结转移患者术前接受贝伐单抗和信迪利单抗治疗后行根治性切除的病例报告

阅读:2

Abstract

Hepatocellular carcinoma with lymph node metastasis (HCC-LNM) is relatively rare, and optimal management remains controversial. We report two cases of HCC with lymph node metastasis treated with three cycles of Sintilimab and Bevacizumab therapy. The metastatic lymph nodes demonstrated partial shrinkage, with extensive coagulative necrosis and complete absence of viable tumor cells. Primary liver lesions demonstrated a partial response to systemic therapy. Both patients subsequently achieved curative resection. No recurrence occurred during postoperative follow-up (20 months for Case 1; 16 months for Case 2). Collectively, preoperative immunotherapy and targeted therapy has the potential to enable curative outcomes in patients with solitary HCC lymph node metastasis, although validation in larger studies is required.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。